The Mycobacterium abscessus MAB-10 strain was set-up in a 40 days in-vitro culture and different drugs combinations were tested. Combinations of bedaquiline (a new anti-tuberculosis drug), amikacin, rifabutin, moxifloxacin, clofazimine (an anti-leprosy drug) and metronidazole (an anti-anaerobic drug) were the most promising, futhermore, bedaquiline and amikacin combinations were the most active against MABs in both anaerobic and dormient phases (dormant persisters). From the results of the tests, the researchers observed that dormant persisters cells living in the biofilm are more difficult to kill than those found in the aerobic phase. The research team believes that prolonged treatment for periods greater than 49 days with these combinations can kill cells from clinical strains in both the aerobic and dormant phases. The most promising combinations will be identified by the results of the experiments that measure the minimum concentration at which the drug is active. The data on the efficacy of drugs in relation to the duration of incubation may explain why MAB-infected CF patients need months of antibiotic therapy. The research group’s work continues with the FFC#17/2021 project in which Dr. Fattorini, given his retirement, passes the coordination to Dr. Federico Giannoni.